important clinical implications. Anti-NMDAR encephalitis is caused by IgG-type autoantibodies to the GluN1 subunit of the NMDAR. Conflicting reports have been published regarding the seroprevalence of anti-NMDAR autoantibodies in schizophrenia, ranging from 0% to 8%. 2, 3 Some studies that reported high seroprevalences included patients with schizophrenia with atypical features, such as seizures and movement disorders. We hypothesized that the use of a single antibody detection assay, without any further validation of the findings, may have contributed to the inconsistent findings. 3 Here, we investigated the presence of anti-GluN1
IgG autoantibodies in 475 patients with a schizophrenia spectrum disorder and included the cross-validation of positive samples.
Methods | The current study included 3 cohorts. Cohort 1 involved 415 patients with schizophrenia who were screened over 2 years with a full laboratory screening for studying metabolic changes at the University Psychiatric Center, Katholieke Universiteit Leuven, Kortenberg, Belgium. Samples from this project have been used in the study by van Winkel et al. 4 To account for the pleiomorphic clinical presentation thought to arise from mental disorders associated with autoimmune encephalitis, we included cohort 2, which consisted of consecutively admitted patients who initially presented with psychosis and were finally diagnosed as having schizophrenia. These samples were collected at the Erasmus University Medical Center, Rotterdam, clinic for patients with suspected psychotic disorders. Samples from this project have been used in the study by Schwarz et al. 5 Cohort 3 was from the Genetic Risk And
Outcome of Psychosis (GROUP) Study, a multicenter longitudinal study started in the Netherlands in 2006. Samples from this project have been used in the study by Korver et al. 6 The cohorts described in this article were included in 2 different laboratories working simultaneously on the same research question.
The serum samples of cohorts 1 4 and 2 5 were analyzed using an in-house cell-based assay (CBA) in human embryonic kidney cells expressing human GluN1; cells were fixed with 4% paraformaldehyde. Serum samples were used in a dilution of 1:40. The CBA was validated using NMDARpositive serum samples by interassay and interlaboratory assessment. The plasma samples of cohort 3 6 were analyzed by the CBA from EUROIMMUN (anti-glutamate receptor IIFT test), according to the manufacturer's protocol with a starting dilution of 1:10. Potentially positive samples were crossvalidated by testing them in 2 other participating laboratories by EUROIMMUN CBA (1:10), by the in-house CBA Approval for this study was obtained from the institutional review boards of Erasmus Medical Center, University Medical Center Utrecht, and EPC KU Leuven; written patient consent was obtained. Table shows Discussion | We showed that the prevalence of classic GluN1 IgG autoantibodies in the blood of patients with schizophrenia is very rare. Our results do not support the hypothesis that a significant subpopulation of those diagnosed as having schizophrenia are patients with misdiagnosed anti-NMDAR encephalitis. However, most patients with anti-NMDAR encephalitis are initially seen by a psychiatrist and within a month develop characteristic symptoms of the disease, leading to the diagnosis.
Results | The
1,2 When nonfixed cells were used in the CBA, 23%
of cases showed antibody-positive results without anti-NMDAR encephalitis (false-positive for this disease) 7 ; in contrast, when fixed CBA and validation studies were used, no false-positive results were found. 1 Furthermore, it is known that antibody titers are higher during the acute phase of the disease and the results of 15% of patients test positive only in cerebrospinal fluid. 1 The main limitations of the current study were that cerebrospinal fluid was not available in these patient cohorts, most patients had chronic illness, and assessments of neurological symptoms were not available. Therefore, studies investigating cerebrospinal fluid and serum of a 
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Benzodiazepines in Anxiety Disorders
To the Editor In their Editorial, Moore and colleagues 1 questioned the clinical usefulness of benzodiazepines, emphasized their addicting potential, and questioned why they are not controlled substances, such as barbiturates and opioids. However, their opinions run counter to the evidence that is available. First, benzodiazepines provide an effective pharmacological treatment of anxiety disorders. 2 Their use has been in part supplanted by second-generation antidepressant drugs in recent years but this has occurred without any supporting evidence. Indeed, when benzodiazepines and antidepressants were directly compared in clinical trials, the superiority of benzodiazepines both in efficacy and adverse effect profile emerged. 
